Moleculin Biotech Inc.

12/17/2025 | Press release | Distributed by Public on 12/17/2025 07:33

Moleculin Announces Positive Results from Phase 1 Clinical Trial Evaluating WP1066 for the Treatment of Pediatric Recurrent Malignant Brain Tumors

Read this content
Click here to read the original version at the source's official website. The text of this article is not available at the moment.
Moleculin Biotech Inc. published this content on December 17, 2025, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on December 17, 2025 at 13:33 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]